newsfilter
← Earnings
Earnings Releases·

Viridian Therapeutics — Third Quarter 2026 Earnings Summary

Viridian Therapeutics reported $24.7 million in net product revenue from its drug Lumvoa during the third quarter of 2026, with over 100 patients currently on therapy. The company maintains a cash position of $955.2 million as of September 30, 2026, and expects to submit a Biologics License Application for its investigational drug elegrobart in the first quarter of 2027. Additionally, Viridian plans to initiate a Phase 1 clinical trial for its TSHR program candidate VRDN-292 in late 2026 and disclose Phase 1 data for VRDN-008 in the fourth quarter of the same year.

Company
VIRIDIAN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology